In a 2025 multicenter cohort study, semaglutide was not associated with an increased NAION risk among individuals with type 2 diabetes compared with non-GLP-1RA antidiabetics but had an HR of 1.44 (95% CI, 0.78-2.68)
This is consistent with our observations related to signal propagation and compartmentalized GLP-1R activity by BRET and confocal microscopy
R., Ara Mimi, A., Aktar Suchi, S., & Xiao, J
View the Gut Healing Foundation Kit Not ready to jump into peptides yet
If you are ready to explore the Wegovy weight loss reality and Zepbound weight loss truth with a team that puts your health first, contact Pure Med Spa today
A part of Watch Medier Stay ahead of development by receiving our newsletter on the latest sector knowledge